RT @JHMaley: Great new read: #tocilizumab in people with #COVID19 admitted to #ICU. COVACTA pre-print of the prior Roche trial for referen…
RT @ventilacionmeca: Estudio con Tocilizumab en pacientes críticos. Ojo es un estudio no aleatorizado. Early Treatment With Tocilizumab a…
RT @umichCVC: Dr. @salimhayek and the STOP-COVID investigators' latest: Association Between Early Treatment With Tocilizumab and Mortality…
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 | Critical Care Medicine | JAMA Internal Medicine | JAMA Network @SShaefi @BIDMChealth https://t.co/piMUYgjGC1
RT @JHMaley: Great new read: #tocilizumab in people with #COVID19 admitted to #ICU. COVACTA pre-print of the prior Roche trial for referen…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @Boghuma: https://t.co/E8wZNdtxMs - 3924 patients in this cohort study. Early use of Tocilizumab within 2 days of ICU admission reduced…
RT @AnilMakam: In as a good of an observational cohort study as possible, the suggested effect size for tocilizumab is massive for critical…
RT @kevingblyth: Reduced #COVID19 mortality assoc with receipt of Tocilizumab @JAMAInternalMed https://t.co/hgmjH29VXg N=3924 BUT only obse…
RT @mikejohansenmd: This seems like a well conducted cohort study; it will (and should not) have impact on anything. I'm coming to think th…
RT @Interasma: Top story: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 |…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @wszczeklik: TOCILIZUMAB - kolejne badanie z dzisiejszego JAMA. Lek wczesnie zastosowany na intensywnej terapii (433 osoby otrzymały lek…
RT @wszczeklik: TOCILIZUMAB - kolejne badanie z dzisiejszego JAMA. Lek wczesnie zastosowany na intensywnej terapii (433 osoby otrzymały lek…
@bfialek @wszczeklik a jednak zmniejsza, w takim razie zupełnie nie rozumiem notki prasowej Roche https://t.co/Ip60YToWcY
#COVID19 updates Zinc deficiency: https://t.co/75zPgrFWWx Tocilizumab: https://t.co/3xPXZEoLEA Tocilizumab: https://t.co/7PWBJZmIwH Hydroxychloroquine:https://t.co/pKU6g3AawO @drharshvardhan @ICMRDELHI @MoHFW_INDIA @republic #Covid_19 #COVID__19 #facemas
Cześć Twitter ☕️ Dzisiaj kolejny rekord w wiadomej dziedzinie (10 000) i w generowaniu chaosu w walce z pandemią służb medycznych i racjonalnej części społeczeństwa. Dlatego witam się małą dobrą wiadomością Profesora Szczeklika👇💪😷
Este es el primer artículo: https://t.co/UuPctc5z7h Y este es el segundo artículo: https://t.co/rOLe7yYzB1 Ambos publicados en @JAMAInternalMed
RT @dnunan79: It was @WorldEBHCDay yesterday I led a chat on #EducatingEBHC A key thing that came up was how COVID-19 has reiterated the…
Estudio con Tocilizumab en pacientes críticos. Ojo es un estudio no aleatorizado. Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/OSL2bW7mWV a través de @JAMAInternalMed part of @JAMANetwork
RT @wszczeklik: TOCILIZUMAB - kolejne badanie z dzisiejszego JAMA. Lek wczesnie zastosowany na intensywnej terapii (433 osoby otrzymały lek…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
RT @kevingblyth: Reduced #COVID19 mortality assoc with receipt of Tocilizumab @JAMAInternalMed https://t.co/hgmjH29VXg N=3924 BUT only obse…
It was @WorldEBHCDay yesterday I led a chat on #EducatingEBHC A key thing that came up was how COVID-19 has reiterated the need for large, simple RCTs for drug interventions, especially when chasing small/moderate effects See replies to this tweet for a
3924 hasta üzerinde yapılan bir çalışmada, yoğun bakıma yatan ciddi COVID-19'lu hastalarda ilk iki günde "Romatoid artit"'li hastalarda kullanılan "tocilizumab"' uygulamasının ölüm oranını azalttığı gösterildi.. https://t.co/wRidgwysi3
RT @kevingblyth: Reduced #COVID19 mortality assoc with receipt of Tocilizumab @JAMAInternalMed https://t.co/hgmjH29VXg N=3924 BUT only obse…
En este estudio no randomizado retrospectivo de pacientes adultos con #COVID19 ingresados en UCI, el uso de tocilizumab en las primeras 48 horas se asoció a una menor mortalidad. 👉 https://t.co/wEzuHzIWOR https://t.co/nycftkAq9U
Is #tocilizumab a promising therapy in severilly ill #COVID19 patients? The results of a large cohort including 4485 adults with COVID-19 admitted to ICU https://t.co/MRn4eGF8uH via @JAMAInternalMed part of @JAMANetwork
RT @crisdelgor75: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/IBygFgqJlz vía @J…
RT @wszczeklik: TOCILIZUMAB - kolejne badanie z dzisiejszego JAMA. Lek wczesnie zastosowany na intensywnej terapii (433 osoby otrzymały lek…
Cohort study among critically ill #COVID19 patients: Risk of in-hospital mortality was lower in patients treated with tocilizumab in the first 2 days of ICU admission compared with patients whose treatment did not include early use of tocilizumab. http
10-20-2020: Here's a more detailed write-up of the Leaf & Gupta clinical trial from Massachusetts, which gave Actemra (tocilizumab) to 433 out of the 3924 patients. Like the majority of Actemra studies, the drug ends up being given to the sicker pati
😊 👌
The observational study https://t.co/EePRjC4Jwz included an important subset of participants with mechanical ventilation, whereas the RCTs did not! Therefore we should not attribute the effect to residual confounding. Still... (2/4)
RT @KiraNewmanMDPhD: For those interested— The RCTs: https://t.co/NvQC8k2EFI https://t.co/mNukfAZlQB The cohort study: https://t.co/PQZQ…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
Great article from STOP COVID!! @_MiguelHernan @DavidLeaf9 Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 | Critical Care Medicine | JAMA Internal Medicine | JAMA Network https://t.co/eCL4
Tal cual !!!
RT @DavidLeaf9: Congrats to all the STOP-COVID Investigators on this important work! Early Treatment With Tocilizumab and Mortality Among…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
Cohort studies have a weird way of finding large effect sizes that seem to go unnoticed in RCTs.
Estos estudios no aleatorizados que hablan de mortalidad solo confunden y dan alas a seguir usando algo que no ha demostrado mejorar sobrevida: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
RT @JHMaley: Great new read: #tocilizumab in people with #COVID19 admitted to #ICU. COVACTA pre-print of the prior Roche trial for referen…
RT @KiraNewmanMDPhD: For those interested— The RCTs: https://t.co/NvQC8k2EFI https://t.co/mNukfAZlQB The cohort study: https://t.co/PQZQ…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
Top story: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 | Critical Care Medicine | JAMA Internal Medicine | JAMA Network https://t.co/IskAJ19NMc, see more https://t.co/CpGiFuOOYd
RT @wszczeklik: TOCILIZUMAB - kolejne badanie z dzisiejszego JAMA. Lek wczesnie zastosowany na intensywnej terapii (433 osoby otrzymały lek…
RT @AnilMakam: In as a good of an observational cohort study as possible, the suggested effect size for tocilizumab is massive for critical…
RT @FralickMike: It is a sad state of affairs when the RCT of tocilizumab has 60 patients who got the drug, but the observational study has…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @RealTimeCOVID19: Just out! 2 RCTs showed NO benefit with #Tocilizumab; 1 non-RCT study showed mortality benefit if given within 2 days…
RT @Abraham_RMI: Interesting study. However, I must say that it is a low quality of evidence to justify the efficacy of #tolicizumab withou…
1,463/ USA (adult current smoking rate was 13.7% in 2018) Of 3,924 ICU patients, 5.2% were current tobacco users https://t.co/toUkEUHjWP
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
Just out! 2 RCTs showed NO benefit with #Tocilizumab; 1 non-RCT study showed mortality benefit if given within 2 days of ICU admission. #RealTimeCOVID #COVID19 @IDSAInfo @SCCM @SCCMPresident @SIDPharm https://t.co/rA8oTtWA7v https://t.co/vbjmAJ1rEM http
RT @FralickMike: It is a sad state of affairs when the RCT of tocilizumab has 60 patients who got the drug, but the observational study has…
#COVID19 #Tocilizumab - 3 new trials. 2 RCT 1 cohort @JAMAInternalMed. No difference in mortality in RCTs. Still absence of compeling evidence for #toci... Maybe IL-6 not the panacea! Cohort: https://t.co/mjhDHwSYTs RCT1: https://t.co/YDy8zfGawy RCT2: htt
RT @umichCVC: Dr. @salimhayek and the STOP-COVID investigators' latest: Association Between Early Treatment With Tocilizumab and Mortality…
RT @FralickMike: It is a sad state of affairs when the RCT of tocilizumab has 60 patients who got the drug, but the observational study has…
RT @umichCVC: Dr. @salimhayek and the STOP-COVID investigators' latest: Association Between Early Treatment With Tocilizumab and Mortality…
Dr. @salimhayek and the STOP-COVID investigators' latest: Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 in @JAMAInternalMed: https://t.co/M6yizBDjxv
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
As with so many things in medicine, if applications had been made and people been randomised we would have “the” answer to so many conundrums. Hunches are irrelevant, compassionate use of non-trialled therapy is irrelevant. The best thing for your patients
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
Reduced #COVID19 mortality assoc with receipt of Tocilizumab @JAMAInternalMed https://t.co/hgmjH29VXg N=3924 BUT only observational @Roche COVACTA RCT already negative ⬇️ Crying shame patients weren’t randomised, size might have revealed sub-group responde
RT @FralickMike: It is a sad state of affairs when the RCT of tocilizumab has 60 patients who got the drug, but the observational study has…
Swiatelko w tunelu! Damy rade!
RT @AnilMakam: In as a good of an observational cohort study as possible, the suggested effect size for tocilizumab is massive for critical…
Among critically ill patients with COVID-19, early treatment with Tocilizumab may ⬇️ mortality, although the findings may be susceptible to unmeasured confounding & further research from RCTs is needed, write @salimhayek et al
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @KiraNewmanMDPhD: For those interested— The RCTs: https://t.co/NvQC8k2EFI https://t.co/mNukfAZlQB The cohort study: https://t.co/PQZQ…
RT @wszczeklik: TOCILIZUMAB - kolejne badanie z dzisiejszego JAMA. Lek wczesnie zastosowany na intensywnej terapii (433 osoby otrzymały lek…
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 Estudio multicéntrico OBSERVACIONAL RETROSPECTIVO. N=3924, UCI. https://t.co/gjH0NjhEvI a través de @JAMAInternalMed part of @JAMANetwork
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
For those interested— The RCTs: https://t.co/NvQC8k2EFI https://t.co/mNukfAZlQB The cohort study: https://t.co/PQZQrYwX4P
RT @IanMedical: De como no se deben hacer las cosas y de como no debemos sacar conclusiones (posiblemente erróneas) de estos estudios https…
1st of 3 studies today in @JAMAInternalMed on tocilizumab in #COVID19 Take home -> Not overly convincing, but there is signal for benefit, maybe? Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/IBygFgqJlz vía @JAMAInternalMed part of @JAMANetwork
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @DavidLeaf9: Congrats to all the STOP-COVID Investigators on this important work! Early Treatment With Tocilizumab and Mortality Among…
De como no se deben hacer las cosas y de como no debemos sacar conclusiones (posiblemente erróneas) de estos estudios
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
How to reconcile today's data on tocilizumab in #COVID19 in JAMA IM? Small RCT shows dubious benefits in non-ICU patients Large obs study w/ multiple adjustments suggests Tx benefit in first 2 days of ICU admission #EBM https://t.co/bM7ZzuX3ek https:
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @wszczeklik: TOCILIZUMAB - kolejne badanie z dzisiejszego JAMA. Lek wczesnie zastosowany na intensywnej terapii (433 osoby otrzymały lek…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
Very large effect to be true, and preliminary trial data show no effect. We need to be very careful in interpreting observational data after failing in 4 Covid-19 treatment experiments https://t.co/RqOCdu58O9
RT @wszczeklik: TOCILIZUMAB - kolejne badanie z dzisiejszego JAMA. Lek wczesnie zastosowany na intensywnej terapii (433 osoby otrzymały lek…
RT @wszczeklik: TOCILIZUMAB - kolejne badanie z dzisiejszego JAMA. Lek wczesnie zastosowany na intensywnej terapii (433 osoby otrzymały lek…
RT @wszczeklik: TOCILIZUMAB - kolejne badanie z dzisiejszego JAMA. Lek wczesnie zastosowany na intensywnej terapii (433 osoby otrzymały lek…
TOCILIZUMAB - kolejne badanie z dzisiejszego JAMA. Lek wczesnie zastosowany na intensywnej terapii (433 osoby otrzymały lek) zmniejszał śmiertelność (HR, 0.71; 95% CI, 0.56-0.92). Dobre wiadomości (z zachowaniem ostrożności - bad. obserwacyjne). https://t
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/3IwMZvRMWz a través de @JAMAInternalMed part of @JAMANetwork
RT @_MiguelHernan: In largest #observational study of #COVID19 patients in ICU, we find: mortality hazard ratio 0.71 (95% CI 0.56-0.92) f…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…